Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. announced the closing of their business combination on September 22, 2025.
The combined company will operate as 'Semnur Pharmaceuticals, Inc.' and its shares of common stock and warrants are expected to begin trading on the OTC Markets on September 23, 2025, under the ticker symbols 'SMNR' and 'SMNRW', respectively.
This completion provides Semnur with access to public capital markets to enhance its business growth and advance its mission to address non-opioid pain management needs, particularly by accelerating the second Phase 3 clinical development in SP-102.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.